Management Financial

Philip R. Cupero

*** ******* *****, *******, ** *5758 256-***-**** *******@******.***

Senior Finance Executive: CFO / Vice President / Director

Accounting / Reporting / Treasury / Budgets & Forecasts / Restructuring / Cost Control / IT /

Business Planning / Tax / Capital Management / Credit / Mergers & Acquisitions / Divestitures

Record of growing and improving operations and corporate financial health while reducing costs in challenging business environments. Experienced in successful Mergers, Acquisitions & Divestitures. Adept at cost control, process improvement and the comprehensive management of financial demands ranging from cash flow analysis to restructuring. Successful in managing banking relationships and credit facilities. Expertise in ensuring good corporate governance critical to both domestic and international financial reporting. Experience in the pharmaceutical, flavors and fragrances, chemical, entertainment and software industries. Excellent staff management and training skills.

MBA in Finance, University of Connecticut

BS in Accounting, Bentley University

Key Accomplishments

Member Sr. Management Team, which significantly grew Qualitest Pharmaceuticals over 7 years. Increased revenues in 2008 to 2015 from $240 million to $1.2 billion; EBITDA from $70 million to $475 million; and Employees from 550 to 2100. Company was purchased for $875 million in 2007 and had an estimated value by 2015 of $6 billion.

Finance lead on Divestiture Team which sold Qualitest to Endo Pharmaceuticals. Finance leader of Divestiture Team in 2010, which sold Qualitest to Endo Pharmaceuticals for $1.2 billion creating over $325 million of value for our investment partners APAX. Led exercise on assembling all financial projections, valuations and presentations to perspective buyers.

Finance lead on multiple acquisition and integration teams. Finance lead on acquisitions and integration of Teva Oral Contraceptives; Par Immediate Release products; Companies Boca and Dava, which sold Immediate Release and Controlled Substance products.

Managed Company thru 2008 Credit Crisis. Successfully managed company’s cash position, banking relations, and $475 million credit facility during the 2008 credit crisis.

Extensive Project Management Successes. Extensive project management experience with process and system implementations; including hardware infrastructure upgrades; Sarbanes Oxley; and company wide reengineering efforts. Projects under my leadership have never missed a budget or deadline.

Career History

Partner, MTP Group – April 2016 to Present

Partner in buying group with 2 other former Qualitest Sr. Management Team colleagues. Primary objective an acquisition in the Generics Pharmaceutical industry and to be installed in the new company as the Management Team. Secured Private Equity Partner and signed confidentiality agreement. Worked with PE, Banks and Consultants (PWC & McKinsey) to target and evaluate potential acquisitions.

Vice President of Finance, Qualitest Pharmaceuticals / Endo Health Solutions Inc. – December 2010 to April 2015

Position report to Sr. Vice President of Qualitest Pharmaceuticals and was a member of the Executive Leadership Team for the business. Position was responsible for: General & Cost Accounting; Financial Operations Credit & Collection, Payroll and Accounts Payable; Financial & Management Reporting; FP&A; and Government Pricing. Directed department of 19 Professionals and 18 Clerical

Key accomplishments: Member of Sr. Management Team which grew annual revenues 200% to $1.2 billion and work force from 1200 to 2100 employees; integration of Qualitest Finance in to Endo Health Solutions Finance; implementation of Sarbanes Oxley; developed and implemented process for evaluating and prioritizing R&D projects.

Finance lead on the acquisitions and integration of the companies: Boca ($200 million purchase price) and Dava ($600 million purchase price), which were comprised of Controlled Substance and Immediate Release products.

Chief Financial Officer, Qualitest Pharmaceuticals / APAX Partners – January 2008 to December 2010

Position reported Chief Executive Officer and a member the Executive Leadership Team for the business. Position was responsible for all aspects of Finance including Treasury, Tax and Risk Management along with Information Technology. Directed departments of 14 professionals and 16 clerical in Finance; and 13 professionals in Information Technology.

Key accomplishments: Member of Sr. Management Team, which grew revenues 48% from $240 million to $400 million and employees from 550 to 1200; successfully managed company’s cash position and $475 million dollar credit facility thru 2008 credit crisis; initiated and managed major restatement of company’s books and records shortly after joining company in 2008.

Finance lead on the divestiture of Qualitest to Endo Pharmaceuticals for $1.2 billion creating $325 million in value for APAX, our investment partners

Finance lead on the acquisitions and integrations of the Teva Oral Contraceptive Product line and Par Immediate Release Products

Director Financial Planning & Analysis, KV Pharmaceutical – April 2004 to December 2007.

Recruited to provide financial support to KV Pharmaceutical and their 3 business units totaling $440 million in revenue. Key responsibilities included: operational and management reporting; the annual budgeting process including capital budgeting; P&L and cash forecasting; assisting with 7 year planning cycle and various ad-hoc business analysis. Directed 3 Business Unit Controllers.

Designed and implemented new Government Pricing department, which prepared pricing calculations (AMP, Best Price, Non-FAMP) for submission to various government agencies.

Developed and implemented monthly management report, which included key performance metrics for our businesses. Key performance metrics included: price / volume, contribution and gross margin by product; manufacturing variance analysis; sales productivity measures; working capital ratio’s; profitability by customer, product and asset along with EVA calculations.

Designed pricing model for our generic business, leading to improved pricing decisions and winning new business.

Chief Financial Officer, Clariant Corp. / BTP plc, U.S. LSE Division – June 1999 to March 2004.

Recruited to manage all financial and reporting functions for two divisions totaling $350 million in revenue. Prepare annual budgets, forecasts and oversee accounting function for U.S. manufacturing sites. Manage a $5 million budget and a staff of 32.

Responsible for U.S. Statutory and UK GAAP reporting, capital expenditure control and management reporting. Manage treasury function including tax, bank relations and foreign currency exposure.

Redesigned pricing model, leading to $9 million in sales with 11% return.

Director of Finance, Rhone-Poulenc Inc. / Rhodia, Inc. – June 1985 to May 1999.

Managed the financial reporting and analysis for World Wide Pharmaceuticals and North American Organics Intermediates. Responsibilities included budgeting, cost accounting and information technology. Analyzed business portfolio to support decisions on divestitures, acquisitions and joint ventures.

Led financial reengineering project that saved $3 million annually. Rapid growth through acquisitions created fragmented processes, duplicate systems and numerous non-value activities. Led project to reengineer accounts payable, general ledger and financial reporting. Developed "Balance Business Scorecard", which had both financial and non-financial measures for the businesses.

As Director of Management Reporting and Analysis, provided financial strategies, recommendations and guidance to Sr. Management for a $1.5 billion specialty and commodity chemical business.

While serving as Director of Finance in the North American Agricultural Division, directed a staff of 11 professionals performing FP&A function.

Promoted 8 times in 14 years to positions of increased responsibility.

Senior Accountant, CBS, Inc. – June 1983 to June 1985.

Accountant, Logica, Inc. – June 1982 to June 1983.

Contact this candidate